Keywords: r-pr, eps, rise, drives, parent, co, 3rd
R-PR's 18% EPS Rise Drives Parent Co In 3rd Qtr
Article | 04 November 1996
Franco-American pharmaceutical company Rhone-Poulenc Rorer reported a pro forma increase in earnings per share in the third quarter of 1996 of 18% ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
